In a report issued on May 5, Brian Skorney from Robert W. Baird maintained a Buy rating on VistaGen Therapeutics (VTGN – Research Report), with a price target of $9.00. The company’s shares closed last Friday at $1.27, close to its 52-week low of $1.06.
According to TipRanks.com, Skorney has 0 stars on 0-5 stars ranking scale with an average return of -7.0% and a 41.6% success rate. Skorney covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Vertex Pharmaceuticals, and Enanta Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for VistaGen Therapeutics with a $7.00 average price target.
Based on VistaGen Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $357.9K and GAAP net loss of $10.54 million. In comparison, last year the company earned revenue of $313.6K and had a GAAP net loss of $5.3 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of new generation medicines to treat diseases and disorders of the central nervous system. Its portfolio focuses on three clinical-stage product; neuropathic pain (NP), levodopa-induced dyskinesia (LID), social anxiety disorder (SAD) and suicidal ideation (SI). Its product include AV-101 product and PH10 neuroactive nasal spray.The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.
Read More on VTGN:
- Mettler-Toledo (MTD) Gets a Hold Rating from Robert W. Baird
- Argenx Se (ARGX) Receives a Buy from Robert W. Baird
- Robert W. Baird Maintains Their Hold Rating on Texas Roadhouse (TXRH)
- Paylocity (PCTY) Receives a Buy from Robert W. Baird
- Robert W. Baird Thinks Definitive Healthcare Corp’s Stock is Going to Recover